摘要
目的探讨miR-141-3p及其靶基因在结直肠癌患者血浆中的表达,及其与临床病理和治疗预后的关系。方法收集结直肠癌患(试验组)者手术前后的血浆和健康志愿者(对照组)血浆各150例,利用实时定量聚合酶链反应(RT-qPCR)检测血浆中miR-141-3p、磷酸酶与张力蛋白同源物(PTEN)、转化生长因子Ⅱ型受体(TGF-β2)和p53的表达水平,统计分析其与结直肠癌病理特征和手术疗效的相关性。结果手术前与对照组比较,试验组血浆中miR-141-3p和p53的表达显著上升(P<0.01),而PTEN和TGF-β2的表达则显著下降(P<0.01)。手术后,试验组血浆中miR-141-3p和p53的表达显著下调(P<0.05),而PTEN和TGF-β2的表达则显著上调(P<0.05)。miR-141-3p的表达水平与结直肠癌肿瘤分化和浸润程度、TNM分期及转移等有显著相关性(P<0.05)。miR-141-3p高表达患者的术后复发率较高、生存率也较差(P<0.05)。结论血浆miR-141-3p在结直肠癌临床诊断和治疗预后中有潜在应用价值。
Objective To investigate the expressions of miR-141-3p and its target genes in the plasma of patients with colorectal cancer,and the relationship with clinicopathological characteristics and prognosis.Methods Plasma of 150 colorectal cancer patients(the experimental group)before and after surgery and 150 healthy volunteers(the control group)were collected.The expression of miR-141-3p,phosphatase and tensin homolog deleted on chromosome 10(PTEN),transforming gromth faetor-β2(TGF-β2)and p53 in plasma were detected by real-time quantitative polymerase chain reaction(RT-qPCR).Its correlation with the clinicopathological characteristics and surgical efficacy of colorectal cancer was statistically analyzed.Results Compared with the control group,the expression of miR-141-3p and p53 in the experimental group significantly increased(P<0.01),while the expression of PTEN and TGF-β2 significantly decreased(P<0.01).After operation,the expression of miR-141-3p and p53 was significantly down-regulated(P<0.05),while the expression of PTEN and TGF-β2 was significantly up-regulated(P<0.05).The expression of miR-141-3p was significantly correlated with the tumor differentiation and invasion,TNM stages and metastasis(P<0.05).Patients with miR-141-3 p high expression showed a higher recurrence rate(P<0.05)and a worse survival rate(P<0.05).Conclusion Plasma miR-141-3 p showed potential value in clinical diagnosis and prognosis of colorectal cancer.
作者
张同
施承民
徐玉
舒若
曾玉剑
孙亮
田衍
肖博凯
李庆
王昆华
罗华友
ZHANG Tong;SHI Chengrnin;XU Yu;SHU Ruo;ZENG Yujian;SUN Liang;TIAN Yan;XIAO Bokai;LI Qing;WANG Kunhua;LUO Huayou(Department of Gastrointestinal and Hernia Surgery,the First Affiliated Hospital of Kunrning Medical University/Yunnan Institute of Digestive Diseases/Yunnan Engineering Technology Center of Digestive Disease,Kunrning,Yunnan 650032,China)
出处
《重庆医学》
CAS
2019年第1期76-79,共4页
Chongqing medicine
基金
云南省消化病研究所内设机构项目(2016NS0085)
云南省科技厅-昆明医科大学联合专项面上项目[2017FE467(-038)]
云岭学者项目(YLXL20170002)